SARISA Therapeutics

Sarisa Therapeutics is a private biotechnology company focused on the development of next-generation peptide-based therapies for metabolic disorders, including obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Founded by renowned peptide chemist Dr. Richard DiMarchi, the company leverages expertise in multi-agonist pharmacology to create unimolecular compounds that target the GLP-1, GIP, and glucagon receptors. These multi-agonists aim to provide superior weight loss and glycemic control compared to existing mono- or dual-agonist treatments. Sarisa is currently in the pre-clinical stage, advancing a pipeline of highly potent and long-acting incretin mimetics. The company is backed by leading venture capital firms and operates out of Bloomington, Indiana.